AstraZeneca Scores High in Guru Fundamental Analysis

AstraZeneca PLC (ADR) receives a strong 77% rating from Validea's P/B Growth Investor model, indicating potential for future growth. Investors should consider the firm's underlying fundamentals as the company passes several key financial criteria.

Date: 17-03-2025

AI Rating: 7

Earnings Per Share (EPS): The report does not provide specific details regarding the EPS for AstraZeneca. Therefore, no analysis can be provided in this area. Revenue Growth: There is no information regarding revenue growth mentioned in the text. As a result, this aspect cannot be analyzed as it is not included. Net Income: The report does not reference net income, which prevents us from analyzing this metric. Profit Margins (Gross, Operating, Net): No profit margin data is presented in the text, meaning an analysis of profit margins cannot be conducted. Free Cash Flow (FCF): There is no mention of Free Cash Flow in the report, limiting any potential analysis in this area. Return on Equity (ROE): The analysis focuses on several key performance indicators, namely the return on assets, which indicates a healthy trend. While ROE is not directly mentioned, the return on assets shows positive performance, suggesting effective management and profitability. Moreover, AstraZeneca rates highly with a 77% score, indicating that the stock has some interest from investors according to the P/B Growth Investor model. It meets several strategy tests, such as book-to-market ratio, return on assets, and various cash flow metrics. However, it did not pass all tests, specifically in areas like advertising to assets and research and development to assets, which could be a concern for investors looking for a more balanced approach. Overall, AstraZeneca's position as a large-cap growth stock appears to have enough strong fundamentals to attract investor interest, despite some weaknesses.

Stocks: AZN